Startup profile · funding coverage
Calytrix Bio funding, valuation and investors
Preclinical biotech developing mutant-CALR-targeting antibodies for myeloproliferative neoplasms; agreed to be acquired by Lilly.
Verified company research · funding, investors and latest developments
Keep track of Calytrix Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A (amount undisclosed)
Amount not disclosed · Date not disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · Wellesley Hills, Massachusetts, United States
Investors in latest funding
Lead: J.P. Morgan Life Sciences Private Capital , Westlake BioPartners
Overview
Calytrix Bio is a Wellesley Hills, Massachusetts biotechnology company founded in 2025 by J.P. Morgan Life Sciences Private Capital. It develops a biparatopic investigational antibody designed to target both common Type 1 and Type 2 variants of mutant calreticulin (mCALR), a molecular driver of some essential thrombocythemia and myelofibrosis cases.
On November 16, 2026 it announced a definitive agreement to be acquired by Eli Lilly for up to $1.5B cash, combining an undisclosed upfront payment and additional payments contingent on clinical and regulatory milestones. Neither the legal transaction close date nor future milestone attainability is known. Calytrix remains a private company pending verified closing.
Why Calytrix Bio is interesting
Its November 16, 2026 announced Lilly acquisition carries a maximum contingent consideration of $1.5B, not a disclosed upfront price or completed sale. The lead biparatopic antibody is preclinical; disease-modifying benefit has not been demonstrated in people.
Product & use cases
Research-stage therapy, not a marketed product. Investigational pathway: (1) identify patients with essential thrombocythemia or myelofibrosis whose disease is driven by Type 1 or Type 2 mutant CALR, based on appropriate molecular testing; (2) develop a biparatopic antibody intended to recognize mutant CALR while sparing normal tissue; (3) test mechanism, safety and exposure in preclinical systems; (4) seek authorization for human trials and measure safety and efficacy in staged trials; (5) only if positive data and required regulatory approvals emerge could physicians prescribe a resulting therapy. Calytrix has not reported clinical efficacy, dose, treatment schedule, pricing or commercial launch.
- Investigational disease-modifying treatment research for mutant-CALR-positive essential thrombocythemia.
- Investigational treatment research for mutant-CALR-positive myelofibrosis.
Key facts
- Lilly acquisition announced Nov 16, 2026 for up to $1.5B; actual upfront cash amount undisclosed.
- Milestone payments depend on future clinical/regulatory progress; the maximum is not guaranteed cash.
- Calytrix lead mCALR biparatopic antibody remains preclinical, not an approved medicine.
- Founded by J.P. Morgan Life Sciences Private Capital in 2025; Series A co-led with Westlake BioPartners and subsequent Series B led by Avoro Ventures, with round amounts not disclosed.
Funding history (newest first)
Series A (amount undisclosed)
- J.P. Morgan Life Sciences Private Capital (lead)
- Westlake BioPartners (lead)
Source: Read source · prnewswire.com
Competitive landscape
Edge: The company hypothesizes its antibody could cover both major mutant-CALR classes and achieve disease modification. The breadth, comparative effectiveness, safety and clinical benefit are not yet demonstrated.
For diligence, distinguish preclinical target biology from a patient-ready drug. The unresolved questions are target selectivity, toxicity, effectiveness in Type 1/2 mutation subgroups, resistance, clinical trial design, and which future milestones release the contingent portion of the acquisition price. The absence of a reported upfront price prevents calculation of investor returns.
-
Current cytoreductive and symptom-directed MPN therapies incumbent
Available clinical treatments manage blood counts/symptoms; not direct antibody equivalents.
-
Lilly/Ajax Therapeutics and other MPN investigational medicines adjacent
Companies pursuing disease-modifying mechanisms with different targets or drug modalities.
-
Other mutant-CALR-targeting therapeutics direct
Potential investigational alternatives; clinical comparability and approvals must be checked by molecular indication.
Notable stories
- Original issuer transaction and clinical-program statement, Nov 16 2026: prnewswire.com (external source)
- Independent Reuters corroboration, Nov 16 2026: investing.com (external source)
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Calytrix Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.